FDA PCAC July 2026
The FDA Pharmacy Compounding Advisory Committee convenes July 23–24, 2026 to evaluate the 503A bulk drug substance status of seven peptide compounds. The committee's recommendations will determine whether 503A compounding pharmacies may continue to prepare these compounds under patient-specific prescriptions.
Research reference only. This page summarizes regulatory documentation and peer-reviewed literature. It does not constitute legal or medical advice. For current 503A status, consult the FDA docket directly. Full disclaimer.
What is the PCAC?
The Pharmacy Compounding Advisory Committee (PCAC) is the FDA advisory body that evaluates whether bulk drug substances should be placed on, maintained on, or removed from the 503A positive list — the list of substances that licensed compounding pharmacies may use in patient-specific preparations under Section 503A of the Federal Food, Drug, and Cosmetic Act.
All seven compounds below are currently classified as Category 2: a holding status indicating prior PCAC review found insufficient evidence for immediate positive listing, but no final prohibition has been issued. The July 2026 meeting is the next formal evaluation point. The committee applies a four-factor analysis covering physical-chemical characteristics, safety and effectiveness evidence, historical use in compounding, and the nature of the condition treated.
Three possible outcomes per compound: (1) Category 1 — positive listing, compounding permitted; (2) Category 2 maintained — continued regulatory uncertainty; (3) Restriction — 503A compounding prohibited.
Day 1 — July 23, 2026
4 compoundsBPC-157
Tissue Repair / Cytoprotective
Mechanism: VEGF upregulation, EGR-1 modulation, NO system interaction
Evidence: Sikiric lab, 30+ years preclinical; no completed Phase II RCTs
KPV
Immunomodulatory / Anti-inflammatory
Mechanism: MC3R/MC4R melanocortin signaling, NF-κB suppression, cytokine reduction
Evidence: Dalmasso 2008 IBD model; Kannengiesser 2011 colitis model
TB-500 (Thymosin β-4)
Tissue Repair / Angiogenic
Mechanism: Actin sequestration, VEGF pathway, anti-apoptotic signaling
Evidence: Goldstein lab; cardiac and wound healing animal models
MOTS-c
Mitochondrial Peptide / Metabolic
Mechanism: AMPK activation, AICAR-mediated folate cycle regulation, mitochondrial biogenesis
Evidence: Lee et al. 2015 Cell; Reynolds et al. 2021 Nature Aging
Day 2 — July 24, 2026
3 compoundsDSIP
Neuropeptide / Sleep Regulatory
Mechanism: Neuroendocrine modulation, delta-wave sleep induction, ACTH suppression
Evidence: Monnier 1977 isolation; Graf 1984 human sleep cohort
Semax
Nootropic / Neuroprotective
Mechanism: BDNF/VEGF upregulation, melanocortin receptor binding, antioxidant activity
Evidence: Approved drug in Russia; multiple human cognitive trial data
Epitalon
Bioregulator / Longevity
Mechanism: Telomerase activation, pineal/circadian regulation, anti-tumor in animal models
Evidence: Khavinson et al. 2003 telomerase; Anisimov et al. 2003 longevity
Frequently Asked Questions
When is the FDA PCAC meeting for peptide compounding in 2026?
The FDA Pharmacy Compounding Advisory Committee is scheduled to meet on July 23–24, 2026. Day 1 (July 23) covers BPC-157, KPV, TB-500, and MOTS-c. Day 2 (July 24) covers DSIP, Semax, and Epitalon.
Will compounding pharmacies have to stop dispensing these peptides after July 2026?
Not immediately. The PCAC meeting produces advisory recommendations, not final regulatory actions. FDA then opens a public comment period before issuing a formal determination — a process that typically takes six months to over one year. Compounds remain in their current Category 2 status until a final determination is issued. Researchers and clinicians should monitor the FDA docket for updates.
What does it mean that these compounds have no FDA-approved equivalent?
For all seven compounds under review, no FDA-approved drug contains the compound as an active ingredient. This is their strongest argument for continued 503A availability: the "suitable commercial alternative" criterion that the PCAC uses to evaluate whether compounding is necessary cannot be met when no approved equivalent exists. The committee must determine whether approved drugs in the same therapeutic category (even with different mechanisms) constitute adequate alternatives.
How can researchers stay informed about the July 2026 PCAC outcomes?
Follow the FDA docket for the July 2026 PCAC meeting (Federal Register notice will include docket number). Clinical Peptide will update the PCAC Outcomes Tracker on this site on hearing days. Public comments on proposed 503A determinations are submitted through regulations.gov.